7 Undervalued Biotechnology & Medical Research Stocks for Tuesday, March 21
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Tuesday, March 21 based on AAII’s Stock Grades.Jack Gilleland
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Is Enveric Biosciences Inc (ENVB) Stock a Good Investment?
Learn more about Enveric Biosciences Inc's (ENVB) stock grades for Value, Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.Issac Deleon
Financial Summary
| Share Statistics | ENVB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6.6 | $498.4 | 5% |
|
| Shares Out (Mil) | 4.0 | 42.8 | 13% |
|
| Institutional Ownership | 80.3% | 81.2% | 49% |
|
| Float (Mil) | 4.3 | 44.5 | 11% |
|
| Beta | 1.11 | 0.72 | 66% |
|
| Avg Daily Volume (000s) | 37 | 264 | 26% |
|
| Price Change (52-week) |
(80.1%) | 56.1% | 9% |
|
| Growth | ENVB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | (5.0%) | (2.0%) | 34% |
|
| EPS (5yr) | na | 15.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ENVB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($9) | ($11) | 30% |
|
| EPS (TTM) | ($7.483) | ($0.700) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($7) | 21% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($2) | $493 | 3% |
|
| Valuation | ENVB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.72 | 2.16 | 15% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | ENVB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.3% | na |
|
| ROA | (139.7%) | (21.8%) | 4% |
|
| ROE | (170.0%) | (20.2%) | 5% |
|
| Liabilities to Assets | 9.6% | 32.0% | 6% |
|
| F-Score | 3 | 3 | 18% |
|
Enveric Biosciences, Inc. did not pass any screens on 10/28/2026.
